JP2009533476A5 - - Google Patents

Info

Publication number

JP2009533476A5

JP2009533476A5 JP2009505655A JP2009505655A JP2009533476A5 JP 2009533476 A5 JP2009533476 A5 JP 2009533476A5 JP 2009505655 A JP2009505655 A JP 2009505655A JP 2009505655 A JP2009505655 A JP 2009505655A JP 2009533476 A5 JP2009533476 A5 JP 2009533476A5

Authority

JP

Japan

Prior art keywords

glp

molecule

diketopiperazine

solution

particles

Prior art date

2007-04-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 59
• 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 51
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 51
• 238000000034 method Methods 0.000 claims 30
• BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 24
• 239000002245 particle Substances 0.000 claims 12
• 239000003795 chemical substances by application Substances 0.000 claims 10
• 239000000843 powder Substances 0.000 claims 9
• 239000000203 mixture Substances 0.000 claims 8
• 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 4
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
• 239000002904 solvent Substances 0.000 claims 4
• 239000000725 suspension Substances 0.000 claims 3
• 239000002253 acid Substances 0.000 claims 2
• 239000002585 base Substances 0.000 claims 2
• 230000001851 biosynthetic effect Effects 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 150000002500 ions Chemical class 0.000 claims 2
• 239000011859 microparticle Substances 0.000 claims 2
• 239000003960 organic solvent Substances 0.000 claims 2
• 230000000065 osmolyte Effects 0.000 claims 2
• 108090000765 processed proteins & peptides Proteins 0.000 claims 2
• 230000002685 pulmonary effect Effects 0.000 claims 2
• 150000003839 salts Chemical class 0.000 claims 2
• 239000011780 sodium chloride Substances 0.000 claims 2
• 238000001694 spray drying Methods 0.000 claims 2
• 239000004094 surface-active agent Substances 0.000 claims 2
• 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 1
• 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
• 208000032781 Diabetic cardiomyopathy Diseases 0.000 claims 1
• 208000032928 Dyslipidaemia Diseases 0.000 claims 1
• 208000020358 Learning disease Diseases 0.000 claims 1
• 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
• 208000026139 Memory disease Diseases 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 claims 1
• 208000006011 Stroke Diseases 0.000 claims 1
• 150000007513 acids Chemical class 0.000 claims 1
• 230000001925 catabolic effect Effects 0.000 claims 1
• 206010012601 diabetes mellitus Diseases 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 238000001914 filtration Methods 0.000 claims 1
• 238000004108 freeze drying Methods 0.000 claims 1
• 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 claims 1
• -1 glutaryl Chemical group 0.000 claims 1
• 201000001421 hyperglycemia Diseases 0.000 claims 1
• 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
• 208000028867 ischemia Diseases 0.000 claims 1
• 210000004153 islets of langerhan Anatomy 0.000 claims 1
• 201000003723 learning disability Diseases 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 230000003278 mimic effect Effects 0.000 claims 1
• 208000010125 myocardial infarction Diseases 0.000 claims 1
• 208000015122 neurodegenerative disease Diseases 0.000 claims 1
• 235000020824 obesity Nutrition 0.000 claims 1
• 230000002980 postoperative effect Effects 0.000 claims 1
• 230000001172 regenerating effect Effects 0.000 claims 1
• 230000010410 reperfusion Effects 0.000 claims 1
• 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
• 208000024891 symptom Diseases 0.000 claims 1
• QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 1
• 230000000451 tissue damage Effects 0.000 claims 1
• 231100000827 tissue damage Toxicity 0.000 claims 1
• 238000002054 transplantation Methods 0.000 claims 1